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Background: Due to an increased frequency of vasculitis in FMF patients, many investigators have studied MEFV
mutations in patients with HSP. The aim of the study is to investigate the frequency and clinical significance of MEFV
mutations in Egyptian children with Henoch-Schonlein purpura (HSP). Investigating MEFV mutations in controls may
help in estimating the prevalence of MEFV mutation carrier rate in Egyptian children.
Methods: The study enrolled 90 individuals, sixty children with Henoch-Schonlein purpura (HSP), together with
30 sex-and age-matched apparently healthy controls. The entire study group was screened for 12 common MEFV
mutations using a reverse hybridization assay of biotinylated PCR products.
Results: Patients with HSP had a significantly higher frequency of MEFV mutations (61.7%), when compared to
the apparently healthy control population (36.7%). V726A was the most frequent mutation with an allelic
frequency of 10.8%. Ninety- one percent of patients with MEFV mutations were heterozygous for one mutation,
while 8.1% had a compound heterozygous MEFV gene mutations. The mutation V726A, followed by E148Q, were
the leading mutations, present in 16.6% and in 13.3% of controls.
Conclusions: MEFV mutations may be related to HSP susceptibility in children. The mutations were not
associated with any clinical and laboratory manifestations. Screening for MEFV mutations in larger number of HSP
children may be beneficial to evaluate any possible relationship between certain types of MEFV mutations and
HSP, and compare the HSP MEFV mutations to the types of MEFV mutations associated with FMF.
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Henoch-Schonlein purpura (HSP) is an IgA-mediated im-
mune complex small vessel vasculitis and is the most
common systemic vasculitis in childhood. It is character-
ized by non-thrombocytopenic palpable purpura, abdom-
inal pain, gastrointestinal bleeding, arthritis or arthralgia
and nephritis [1-3]. The exact etiology of HSP is not
known and no specific genetic abnormalities have been
described in HSP patients [4]. Familial Mediterranean
fever (FMF) is a monogenic auto-inflammatory disease
affecting the Mediterranean population and caused by
mutations in the MEFV gene. FMF is characterized by
recurrent febrile episodes, pleurisy, peritonitis, arthritis
and rash and may be complicated by renal amyloidosis,
although wide clinical variability may be present [5,6].* Correspondence: dr_hlotfy@yahoo.com
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unless otherwise stated.Several studies reported an increase frequency of MEFV
mutations among children of vasculitic and rheumatic dis-
eases, like inflammatory bowel disease (IBD), polyarteritis
nodosa (PAN), HSP and juvenile idiopathic arthritis (JIA)
[7-9]. FMF has been reported in patients with HSP and
other systemic vasculitis. The MEFV gene has been sug-
gested to play an important role in the pathogenesis of
this association [7,10]. Also, MEFV mutations have been
suggested to exaggerate inflammatory response in HSP
[8,11].
The aim of the present study is to evaluate the fre-
quency of MEFV mutations in Egyptian children with
HSP and their association with the course and labora-
tory findings of the disease. Also our aim is to help in
estimating the prevalence of MEFV mutations carrier
rate in Egyptian children.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Characteristics of HSP patients and controls
Variable Cases (n = 60) Control (n = 30) P-value
Mean age ± SD 8.1 ± 3 7.67 ± 3 0.66
Range 2-15 5-16
Sex
Boys 29(48.3%) 12(40%) 0.45
Girls 31(51.7%) 18(60%)
*Mutated MEFV gene 37(61.7%) 11(36.7%) 0.03
Sex of children with
mutated
MEFV gene
Boys 16(43.2%) 6(54.5%) 0.51
Girls 21(56.8%) 5(45.5%)
*Odd ratio for mutation vs having the disease = 2.8 (95% CI 1.1-6.9).
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The study enrolled a total of 90 children including 60
patients with HSP diagnosed according to established
criteria of the European League against Rheumatism
(EULAR) and Pediatric Rheumatology European Soci-
ety (PReS) [12]. All were followed up at the pediatric
rheumatology clinic of the Cairo University Specialized
Pediatric Hospital during the period from October
2009 to March 2013. Thirty age-and gender-matched
apparently healthy controls, with no family history or
clinical manifestations suggestive of HSP or FMF, were
assigned to the control group. The age of disease onset
had to be before 18 years for the patient to be included
in the study. Children with previous diagnosis of FMF
prior to the onset of HSP were excluded from the
study. The study was approved by the Cairo University
Clinical Research Ethics Committee, and informed con-
sents were obtained from parents of all participants.
Each enrolled patient was subjected to thorough history
taking, including demographic data and disease duration,
and also a full physical examination with emphasis on signs
of skin, joint, gastrointestinal tract (GIT) and renal involve-
ment were performed. Complete blood count (CBC),
erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP) concentration, anti-streptolysin O titre (ASOT),
blood urea nitrogen, creatinine, urine analysis and occult
blood in stool tests were determined by the standard
laboratory methods at the time of study enrollment.
MEFV gene mutation analysis
Blood samples for mutation analysis were also obtained at
time of study enrollment from either newly diagnosed pa-
tients or previously diagnosed patients following up at the
clinic. All children were screened for 12 MEFV gene mu-
tations (E148Q in exon 2, P369S in exon 3, F479L in exon
5, M6801 [G/C], M6801 [G/A], 1692del [2076–2078],
M694V, M6941, K695R, V726A, A744S, R761H in exon
10) using the FMF Strip Assay, Vienna Lab Diagnostics
GmbH, Vienna, Austria [13]. Genomic DNA was ex-
tracted from peripheral blood with ethylenediamine tetra-
acetic acid (EDTA) by standard procedures. The assay is
based on light cycler real-time quantitative polymerase
chain reaction (RTPCR) and reverse hybridization, suit-
able for determination of MEFV mRNA expression. It in-
cludes PCR amplification by a thermo cycling program of
35 cycles(94°C for 15 seconds, 58°C for 30 seconds and
72°C for 30 seconds) with final extension at 72°C for 3 mi-
nutes, followed by the hybridization of the amplification
products to a test strip containing both wild and mutant
allele-specific oligonucleotide probes immobilized as an
array of parallel lines. Bound biotinylated sequences were
detected using streptavidin-alkaline phosphatase and en-
zymatic color reactions. For each polymorphic position,
one of three possible staining patterns were obtained {wildtype probe only (normal genotype), wild type and mutant
probe (heterozygous genotype), or mutant probe only
(homozygous mutant genotype)}.
Statistical analysis
Chi-Square or Fischer’s exact test (when appropriate)
and Odds ratio were used to assess the association be-
tween qualitative variables. Quantitative variables were
compared by t-student or ANOVA test when appropri-
ate. In all tests, p value was considered significant if less
than 0.05. All statistical calculations were done using
computer programs SPSS (Statistical Package for the So-
cial Science; SPSS inc., Chicago, IL, USA) version 22 for
Microsoft Windows.
Results
The study included 60 Egyptian children with HSP, 31
females and 29 males. Their mean age at disease onset
was 8.1 ± 3 years. The parents of 27% of patients were
consanguineous, and 8.1% of patients had family history
of FMF. The control group included 30 children with a
mean age of 7.67 ± 3. The demographic characteristics of
the study group were summarized in Table 1. Clinical
and laboratory characteristics of the patients were sum-
marized in Tables 2 and 3. All patients had purpura at
the time of diagnosis. Arthritis occurred in 44 patients
(73.3%), abdominal pain in 48 (80%), while gastrointestinal
complication occurred in 14 (23.3%) and hypertension in
4 (6.7%) patients. Thirteen patients (21.7%) showed recur-
rence of HSP. MEFV mutations were detected in 37
(61.7%) of HSP patients, with an allelic frequency of
34.1%, and in 11 (36.7%) of the controls with an allelic
frequency of (18.33%). A statistically significant differ-
ence was detected between patients and controls (p =
0.03). V726A mutation was the leading mutation in
HSP patients, with a frequency of 21.7%, while V726A,
followed by E148Q, were the leading mutations in
Table 2 Characteristics of HSP patients stratified by the presence of MEFV mutations
Variable Mutation(−) At least one mutation(+)
P-valuen = 23 (38.3%) n = 37 (61.7%)




*F.H. of FMF 0(0%) 3(8.1%) 0.279
Arthritis 16(69.6%) 28(75.7%) 0.603
Abdominal pain 18(78.3%) 30(81.1%) 1
GIT complication 5(21.7%) 9(24.3%) 0.818
Hypertension 3(13%) 1(2.7%) 0.153
Recurrence 5(21.7%) 8(21.6%) 1
*F.H of FMF: family history of Familial Mediterranean Fever.
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ively. The MEFV genotypic and allelic frequencies are
summarized in Table 4. Among the 37 HSP patients with
mutated MEFV gene, 34 (91.9%) were heterozygous for
one mutation, 3 (8.1%) were compound heterozygous
and none of our patients had homozygous mutation
(Table 2).
When stratified according to the presence or absence of
MEFV gene mutations, no statistically significant differ-
ences were detected between the 2 groups; regarding
demographic, clinical and laboratory characteristics
(Tables 2 and 3). Although arthritis, abdominal pain, GIT
complication and stool positivity for occult blood were all
more frequently observed in patients with MEFV gene
mutations, differences were not statistically significant.
Eight of 37 patients (21.6%) withMEFV mutation and five
of 23 patients (21.7%) without mutations had one or more
recurrence of their disease with no significant difference
(Table 3). When stratified according to the presence of
V726A gene mutation , non-V726A gene mutation andTable 3 Laboratory investigations of HSP patients stratified b
Variable Mutation (−)









Elevated urea and creatinine 0
Positive stool for occult blood 5(21.7%)
*Anaemia: HB < 10, leucoytosis: TLC > 11,000cells/cmm, thrombocytopenia: plateletwild type mutation, no association was detected between
the type of mutation and demographic, clinical and
laboratory characteristics (Additional file 1: Table S1
and Additional file 2: Table S2).
Discussion
Due to an increased frequency of vasculitis in FMF pa-
tients, many investigators have studied MEFV mutations
in patients with HSP [8,9,11,14]. In the present study,
MEFV mutations were detected in 61.7% of HSP pa-
tients, with a statistically significant difference between
patients and controls (p = 0.03). This high frequency of
MEFV mutations among HSP patients is consistent with
the results of other studies [8,11,14,15].
The frequency of MEFV gene mutation in our HSP
study group is higher than the carrier rate ofMEFV muta-
tion among Egyptian general healthy population (18.4%),
reported in a limited number of studies [16]. The fre-
quency of MEFV gene mutations in our HSP study group
was more than its frequency in Turkey, as reported byy the presence of MEFV mutations
At least one mutation(+)











count < 100,000cells/cmm •elevated ASOT > 400.
Table 4 MEFV gene mutations in HSP patients and controls
HSP patients Controls
(n = 60) (n = 30)
Wild-type, [mutation (–)] 23(38.33%) 19(63.3%)
Presence of MEFV gene mutations 37(61.7%) 11(36.7%)
Heterozygous for one
mutation
p.V726A / – 12(20%) 5(16.6%)
p.E148Q / – 8(13.3%) 4(13.3%)
p.M680I (G/A) / – 8(13.3%) 1(3.33%)
p.M694V / – 5(8.3%) 1(3.33%)
P369S / – 1(1.7%)
Compound heterozygous for two or three mutations: 3(5%)
E148Q/M694V 2(3.3%)
M680I/M694V/V726A 1(1.70%)
Allelic Frequency of MEFV gene mutations
HSP patients Controls
alleles(n = 120) alleles(n = 60)
V726A 13(10.83%) 5(3.15%)
E148Q 10(8.3%) 4(2.5%)
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Also Dogan et al. detected MEFV gene mutations in
24.3% of HSP children, with an allelic frequency of 16.8%
[15]. Our results were also higher than the results of
Gershoni-Baruch et al. who examined 52 HSP children in
Israel (30 Arabs, 22 Jews). These MEFV gene mutations
were detected in 27%, with an allelic frequency of
18.2% [8]. The frequency of MEFV mutations in our
children with HSP is surprisingly high. This difference
may be related to ethnic differences, variations in num-
ber of recruited patients in each study, a higher rate of
consanguineous marriage, and variations in study de-
sign. The frequency of MEFV gene mutation in Egyp-
tian patients with HSP in the present work (61.7%) is
very close to its frequency in Egyptian children with
FMF, reported as (57.6%) in the study of El Gezery
et al. [17] and 60.5% in the work of Ibrahim et al. [18],
but lower than the frequency in the work of El Garf et al.
(97%) [19]. These results may point to the presence of
association between HSP and FMF, but determining such
association will require a larger sample size of HSP and
FMF patients, optimally including a subgroup of HSP pa-
tients with a previous history of FMF for comparison.
In the present study, mutations detected in 34 (91.8%) of
HSP patients were heterozygous ,while only 3(8.1%) hadcompound heterozygous MEFV mutations, which is con-
sistant with the results of Bayram et al. [11] in which (70%)
of HSP patients with MEFV mutations had heterozygous
mutations, 12.7% had compound heterozygous mutations
and 17% had homozygous mutations. Heterozygous muta-
tions were also more prevalent among HSP patients with
MEFV gene mutations in the study of Gershoni-Baruch
et al. [8]. V726A was the commonest mutation detected in
our HSP study group, which is not consistent with the re-
sults of other Turkish studies where M694V was the most
common mutation [11,14]. Our results are also not consis-
tant with the results of Gershoni et al. [8] from Israel and
He et al. [20] from China in which E148Q being the most
frequent mutation among patients with HSP (43% and
85%) respectively. In a study of Iranian HSP patients,
V726A mutation was detected in only 2% of HSP patients
with detected MEFV mutations, while the M694V muta-
tion was the most frequent mutation (22%) [21]. The vari-
ation in the type of genetic mutation between our HSP
patients and patients from other countries may be related
to the genetic heterogeneity of the Egyptian population.
This population is one that has undergone genetic admix-
ture and racial mixing, which created a heavily mixed
population of modern Egyptians including several ethnic
groups such as Bedouins, Peasants, Nubians, Berbers, and
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be less obvious among other ethnic populations. The com-
parison of mutations in HSP patients with history of FMF
may ultimately be beneficial in determining the type of
mutation predisposing to FMF and the types ofMEFV mu-
tations protecting against FMF.
The V726A genetic mutation is the most common mu-
tation in our HSP study group, yet among Egyptian FMF
patients, the most common genetic mutations are quite
different including M6941 in 2 studies [18,23], E148Q
in another study [24] ,and M694V in a recent work of
Al- Haggar et al. in 2014 [25]. While our work does
suggest that the most frequent MEFV mutations associ-
ated with HSP is different from the most common muta-
tions associated with FMF, a study of a much larger
number of HSP patients is needed to confirm this finding.
When stratified according to the presence of MEFV
gene mutations, no statistically significant differences in
clinical manifestations and laboratory findings were de-
tected between HSP patients, similar to the result re-
ported by Gershoni et al. [8]. In contrast, Bayram et al.
[11] and Ozcakar et al. [14] reported that the presence
of MEFV mutations may affect the clinical manifesta-
tions and laboratory findings in HSP.
Our results show that 36.7% of our studied healthy con-
trols were carriers forMEFV mutations with an allelic fre-
quency of 18 .33%. V726A, followed by E148Q, were most
common mutations. These results are higher than the re-
sults of Al-Alami et al. [16], who reported an allelic fre-
quency of MEFV gene mutation among apparently
healthy mixed Arabic population to be 9.3%. It is also
higher than the carrier rate in the Syrian population
(17.5%), with E148Q being the leading mutation, followed
by V726A and M694V [26]. Our MEFV carrier rates are
also higher than the carrier rate found in an Algerian
study (19.13%), with E148Q being the commonest MEFV
gene mutation [27].
The heterogeneity in the genetic mutations between
Egyptian and other Mediterranean countries may be due
to the strategic position of Egypt as a crossroad between
countries, causing a real genetic admixture within the
Egyptian population [28]. Unfortunately, the small num-
ber of studied individuals in the available studies have
not been statistically capable of definitively determining
the carrier rate of MEFV mutations in Egypt. To our
knowledge, this is the first study examining the fre-
quency of MEFV mutations in HSP children in Egypt.
Egypt remains an understudied population for these mu-
tations. As noted, one of the main limitations of the
study is that the present study doesn’t have the statistical
power to determine the relationship of certain MEFV
mutations with HSP susceptibility or disease phenotype or
outcomes. Larger number of studied HSP patients and
controls may be needed in future studies. Further studieswith larger numbers of apparently healthy children may
be also required to establish a data base for the carrier rate
ofMEFV mutations in Egypt.
Conclusion
Our study suggests that the MEFV mutations are much
more frequent in Egyptian HSP children than healthy
controls, especially the V726A mutation. The presence
of MEFV mutations in our HSP children is not associ-
ated with a statistically significant difference in clinical
presentation and laboratory findings. When correlating
our results to other studies from the literature, we be-
lieve that the next step is to study this possible associ-
ation between HSP and FMF MEFV gene mutations in a
much larger number of Egyptian HSP children.
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